Hygieia is the developer of d-Nav, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav's AI-powered technology automatically interprets data and independently initiates insulin management. The d-Nav Insulin Management Program adds clinical support that helps people with type 2 diabetes adjust their insulin doses according to their body's changing insulin needs. Studies have shown that nearly 90 percent of people using d-Nav report lower A1C in just three months* without increasing the risk for hypoglycemia**. The d-Nav Insulin Management Program has been peer-reviewed with studies published in leading medical journals.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/03/23 | $22,000,000 | Series B Extension |
Firstime Venture Capital | undisclosed |
